Zimmer Biomet Holdings Stock News

The global Dental Zirconia Implant market size is projected a CAGR of 8.2% during 2021-2027. Worldwide ""Dental Zirconia Implant Market"" 2021-2027 Industry report examines the development openings just as the dangers to the Dental Zirconia Implant Market regarding Business Tactics,

The Demineralized Bone Matrix (DBM) research report undoubtedly meets the strategic and specific needs of the businesses and companies. The report acts as a perfect window that provides an explanation of market classification, market definition, applications, market trends, and engagement.

Sumitomo Mitsui DS Asset Management Company Ltd cut its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 0.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,952 shares of the medical equipment providers stock after selling 122 shares during the period. []

Symmetry Partners LLC lowered its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 5.8% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 2,970 shares of the medical equipment providers stock after selling 184 shares during the period. Symmetry Partners LLCs holdings in Zimmer Biomet were []

Overview The greatest benefit of bone regeneration or grafting over natural tissue is the speed with which it can occur. Because it is a living tissue, it replaces and develops new bone after trauma or disease. With advancements in modern medicine

Bernzott Capital Advisors raised its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 129.7% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 63,575 shares of the medical equipment providers stock after buying an additional 35,903 shares during the quarter. Bernzott Capital Advisors holdings in Zimmer Biomet were []

Key Companies Covered in the Regenerative Medicine Market Research Report Are Amgen Inc., Novartis AG, Medtronic Plc., Stryker Corporation, CryoLife, Inc., Integra LifeSciences Corporation, 3M Company, AbbVie Inc., Zimmer Biomet, and other key market players. Key Companies Covered in the Regenerative Medicine Market Research Report Are Amgen Inc., Novartis AG, Medtronic Plc., Stryker Corporation, CryoLife, Inc., Integra LifeSciences Corporation, 3M Company, AbbVie Inc., Zimmer Biomet, and other key market players.

The Enzymatic Debridement is the numerous enzymatic debridement agents that have been developed, such as trypsin, streptokinase- streptodornase combination, and subtilisin. However, the two most normally enzymatic agents used for chronic wounds are papain-urea combinations in a cream base and

Market Overview Spine Surgery Devices are medical instruments that are used to fix the vertebrae of the spinal column. They are made from metals, such as titanium, stainless steel, or a combination of these. Once placed in the interbody disc space,

Prominent joint reconstruction devices manufacturers across the globe include Stryker, ConforMIS, Smith & Nephew, NuVasive, Medtronic, Globus Medical, Medacta, Zimmer Biomet, DJO Global, MicroPort Scientific Corporation, and Waldemar LINK. Prominent joint reconstruction devices manufacturers across the globe include Stryker, ConforMIS, Smith & Nephew, NuVasive, Medtronic, Globus Medical, Medacta, Zimmer Biomet, DJO Global, MicroPort Scientific Corporation, and Waldemar LINK.

Thorough understanding of market surely helps to get the best solution for the problem of your customers. Market Research also provides precise overview on industry, market competition, projections for the business, insight into target market and guidelines to follow for

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) shares hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $124.16 and last traded at $124.23, with a volume of 15185 shares traded. The stock had previously closed at $125.62. Several research analysts have recently commented on the stock. Piper Sandler lowered []

The US knee implants market is expected to be highly consolidated owing to the growth in knee implant industry in the entire healthcare sector. Smith & Nephew, Johnson & Johnson, Stryker Corp., and Zimmer Biomet Holdings Inc. are the four

Equities research analysts expect Zimmer Biomet Holdings, Inc. (NYSE:ZBH) to announce $2.06 billion in sales for the current quarter, Zacks reports. Nine analysts have made estimates for Zimmer Biomets earnings, with estimates ranging from $2.04 billion to $2.08 billion. Zimmer Biomet reported sales of $2.09 billion during the same quarter last year, which would suggest []

Zimmer Biomet Holdings Inc (ZBH) shares closed today at 0.6% above its 52 week low of $124.83, giving the company a market cap of $26B. The stock is currently down 18.1% year-to-date, down 15.6% over the past 12 months, and up 27.6% over the past five years. This week, the Dow Jones Industrial Average fell 1.9%, and the S&P 500 fell 2.1%. Trading Activity Trading volume this week was 34.3% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -456.2% The company's stock price performance over the past 12 months lags the peer average by -228.3% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 0.4% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.